China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
This article was originally published in The Pink Sheet Daily
Health care reform in the U.S. is a good opportunity for Fosun to gain a foothold in the U.S. market, company chair says at China's first-ever BIO conference.
You may also be interested in...
Lonza Forms JV With Shanghai Fosun To Tap Chinese Generics Market
Swiss firm Lonza Group AG, a global supplier of active pharmaceutical ingredients has announced a joint venture with Shanghai Fosun Pharmaceutical. The 50/50 JV will develop and launch a portfolio of generic products in China
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).